Cancer immunotherapy can lead to long-lasting responses, yet many tumors remain challenging for immune cells to access, identify, and eliminate. A fresh review highlights how bioactive nanomaterials might tackle these obstacles through three interconnected approaches. Surface-adaptive nanomaterials alter their behavior when moving from the bloodstream into tumors, antigen-engineering platforms render poorly immunogenic cancer cells more noticeable, and tumor microenvironment-modulating systems diminish signals that hinder immune activity. By linking delivery, immune recognition, and local reprogramming, this framework provides design principles for nanomedicines that could boost antitumor responses, enhance treatment accuracy, and restrict unnecessary immune activation in healthy tissues across various tumor types.
Immune checkpoint inhibitors, cancer vaccines, and cellular therapies have transformed oncology, but most patients still fail to achieve lasting benefits. Solid tumors construct layered defenses: abnormal blood vessels and dense tissue impede drug access, unstable antigen expression weakens immune recognition, and suppressive cells, cytokines, and metabolic conditions exhaust tumor-fighting lymphocytes. Systemic stimulation can also trigger immune-related adverse events, creating a delicate equilibrium between potency and safety. Nanomaterials offer adjustable size, surface chemistry, and cargo capacity, but systems designed around just one barrier may fall short elsewhere in the treatment pathway. Given these challenges, thorough research is needed into integrated nanomaterials that coordinate tumor delivery, antigen presentation, and immune microenvironment reprogramming.
Researchers from Nankai University published (DOI: 10.1007/s10118-026-3567-z) the review online on April 24, 2026, in Chinese Journal of Polymer Science. The study summarizes three complementary nanomaterial strategies aimed at overcoming physiological barriers, enhancing tumor immunogenicity, and alleviating immune suppression, offering a unified framework for developing more precise and effective bioactive nanomaterials for cancer immunotherapy and clarifying how these approaches can be integrated.
The first route centers on surface-adaptive nanomaterials (SANs), which stay relatively stable during circulation but respond to acidity or hypoxia inside tumors. These changes can expose adhesive surfaces, improve tumor retention, or trigger controlled release of immune-regulating cargo. The second route employs antigen engineering to restore immune visibility. Some nanoplatforms anchor immunogenic signals onto tumor-cell membranes, aiding natural killer (NK) cells or tumor-associated macrophages in recognizing malignant cells. Others induce endoplasmic reticulum stress or lysosomal disruption, prompting cancer cells to display immunogenic signals and release damage-associated molecular patterns (DAMPs). Additional systems capture tumor-associated antigens (TAAs) and deliver them to antigen-presenting cells (APCs), particularly dendritic cells (DCs), to support major histocompatibility complex class I (MHC-I) presentation and T-cell activation. The third route reshapes the tumor microenvironment (TME) by concentrating checkpoint inhibitors within tumors, removing suppressive proteins, or regulating immune-related pathways at the gene level. Studies summarized in the review reported stronger tumor control, reduced metastasis, or improved immune activation in mouse models. Across these examples, the authors argue that circulation stability, tumor-selective activation, antigen presentation, and immune reprogramming should be designed as connected functions rather than separate technical objectives.
The authors stated that bioactive nanomaterials should not be regarded simply as passive carriers, but as responsive systems that interact with evolving biological conditions. A clinically useful platform must remain controlled in the bloodstream, activate selectively within tumors, strengthen immune recognition, and reduce local suppression, they said. The authors added that progress will depend on clearer understanding of nano-bio interactions, stronger immune-safety testing, predictable biodistribution, durable immune memory, and manufacturing methods that can deliver reproducible materials at clinical scale, rather than only dramatic tumor shrinkage in small animal studies.
This framework could support nanomedicines tailored to a patient’s tumor antigens, immune status, and microenvironment. Future platforms may combine programmable materials with engineered cells, ribonucleic acid (RNA) circuits, gene-editing tools, radiotherapy, chemotherapy, or targeted inhibitors to widen therapeutic windows and overcome resistance. Translation will require standardized assessment of cytokine release, complement activation, off-target immune stimulation, pharmacokinetics, clearance, and long-term protection against tumor recurrence. Good manufacturing practice (GMP)-compatible production and quality control (QC) will also be essential for batch consistency, stability, sterility, and scalability. Building these requirements into early design could help move promising preclinical systems toward clinical testing for immunotherapy-resistant cancers.
Citations
DOI
10.1007/s10118-026-3567-z
Original source link
https://doi.org/10.1007/s10118-026-3567-z
Funding sources
This study was financially supported by the National Natural Science Foundation of China (Nos. 52525310, 52373143, 22077073 and 52203172).
Lucy Wang
BioDesign Research
email us here
